Objective: To describe clinical and imaging findings in a group of patients affected by nonsyndromic deafness A9 (DFNA9), using advanced magnetic resonance imaging (MRI) with 3-dimensional (3D) fluid-attenuated inversion recovery (FLAIR) sequence. Method: A retrospective case review was conducted in a tertiary referral center in Italy. Four sequential adult DFNA9-affected patients, who had undergone MRI at our Department between January 2017 and June 2018, were enrolled (male = 2, female = 2; median age: 65.6 years; 8 diseased ears analyzed). Three patients were relatives; the fourth was unrelated. The main outcome measures -age, sex, records of audiological and vestibular testing, genetic assessment, MRI findings -were analyzed. Results: All subjects suffered from bilateral progressive sensorineural hearing loss, more severely at the high frequencies and with a typical clinical pattern of bilateral chronic degenerative cochleovestibular deficit. Aural fullness was reported at the onset of the disease. All patients revealed a pathogenic heterozygous mutation in the Limulus factor C, Coch-5b2 and Lgl1 domain of cochlin. None of the patients showed a significant vestibular and cochlear endolymphatic hydrops at MRI, while high bilateral contrast enhancement on 4-h delayed postcontrast 3D FLAIR sequence was observed in all ears. Conclusions: Increased perilymph enhancement on 4-h delayed postcontrast 3D FLAIR sequence is the common imaging feature of DFNA9 ears, suggesting that blood-labyrinthine barrier breakdown may play the main role in the pathophysiology of this disease. Significant hydrops has been excluded by MRI. This finding might be clinically useful in differentiating DFNA9 disease from other pathologies with similar clinical findings like Ménière's disease.
Introduction
Nonsyndromic deafness A9 (DFNA9) is a cause of autosomal dominant late-onset sensorineural hearing loss associated with progressive bilateral vestibular deterioration [Manolis et al., 1996; Kemperman et al., 2005] . The disease starts with a high-frequency hearing loss and progresses to a poor hearing performance in the 6th and 7th decades [Manolis et al., 1996; Fransen and Van Camp, 1999; Lemaire et al., 2003; Bischoff et al., 2005; Kemperman et al., 2005; Hildebrand et al., 2010] . Given the rarity of the disease [Fransen and Van Camp, 1999; Usami et al., 2003; Chen et al., 2013] and its clinical presentation characterized by fluctuating hearing loss accompanied with intermittent vertigo and dizziness, aural fullness and tinnitus, DFNA9 can sometimes be misdiagnosed as Ménière's disease or dehiscent superior semicircular canal syndrome [De Kok et al., 1999; Lemaire et al., 2003; Hildebrand et al., 2009] . Mutations in the COCH (coagulation factor C homology) gene, found on the long arm of chromosome 14 (14q12-q13), has been linked to the development of the disease [Manolis et al., 1996] . The gene encodes for the cochlin protein, which is highly expressed in the cochlea and in the vestibular system [Robertson et al., 1998; Li et al., 2005; Robertson et al., 2006] . The function of cochlin has yet to be fully understood; it is believed to assist the local immunological response and to provide structural support in the inner ear [Bhattacharya, 2006; Py et al., 2013; Bae et al., 2014] . Although interest is increasing in the genomics and pathophysiology underlying COCH-related disease and DFNA9, information about the morphological appearance at imaging is limited.
Our aim was to describe the imaging findings in a group of consecutive patients affected by DFNA9, using advanced magnetic resonance imaging (MRI) with 3-dimensional (3D) fluid-attenuated inversion recovery (FLAIR) sequence.
Materials and Methods

Subjects
This study was approved by the Institutional Review Board of Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico of Milan, Italy (protocol No. 473_2018, accepted June 19, 2018 . Informed consent was waived. We retrospectively enrolled all sequential patients affected by DFNA9, who had undergone MRI at our Department between January 2017 and June 2018. We also collected 24 consecutive MRI scans of the contralateral "normal" ears (males = 13, females = 11; age range: 25-74 years, median age: 53 years) of patients with unilateral sudden hearing loss, diagnosed according to the American Academy of Otolaryngology -Head and Neck Surgery criteria [American Speech-Language-Hearing Association, 1997]. From an otological viewpoint, contralateral ears were defined as normal according to the following criteria: (1) no history of otological disorders (either middle or inner ear pathology), no report of previous ear surgery and/or no history of previous or current vertigo episodes and/or dizziness, as evidenced by the patient's medical record; (2) normal results at the audiological evaluation with otomicroscopy, pure-tone audiometry, immittance audiometry, transient otoacoustic emissions and speech audiometry; (3) no pathological findings on MRI.
Audiological and Vestibular Assessment
The measurements were all conducted in a sound-attenuated booth fulfilling the requirements of ISO 8253-3 (2012) , at the Audiology Unit, Department of Surgical Sciences, University of Milan, Milan, Italy.
After gathering all relevant clinical information about the onset and progression of hearing loss and any concurrent balance disorders, all subjects underwent the following battery of tests: • Otomicroscopy • Pure-tone audiometry (Amplaid A321, Resonance, Gazzaniga, Italy) with measurement of air conduction thresholds at all octave frequencies between 125 and 8,000 Hz and of bone conduction thresholds between 250 and 4,000 Hz; thresholds were reported as PTA4 = pure-tone average of 0 
MRI Acquisition and Assessment
All patients were imaged on a 3-T scanner (Achieva, Philips Healthcare, The Netherlands) using a 32-channel head coil. The imaging protocol consisted of sequences for both the whole brain and temporal bone assessment, as recommended in MRI of sudden sensorineural hearing loss (SSHL) [Conte et al., 2018a] . In addition, after intravenous contrast agent administration, the protocol included 4-h delayed postcontrast MRI for the evaluation of the membranous labyrinth as accepted in the recent literature [Nakashima et al., 2009; Conte et al., 2017 Conte et al., , 2018b . Contrast agent (gadoteridol, Prohance TM , Bracco Diagnostic Inc., Milan, Italy) was administered intravenously at the recommended dose (0.2 mmol/ kg). MR protocol parameters are listed in online supplementary materials Table 1 (for all online suppl. material, see www.karger. com/doi/10.1159/000501292). A neuroradiologist with 6 years of experience in otoradiology and a senior radiology resident assessed MR images in consensus. For each ear the readers assessed: (1) on T2-weighted 3D steady-state free precession (FFSP) sequence the traverse section of the cochlear nerve on the parasagittal plane perpendicular to the internal auditory canal at the level of the fundus, defining it as "normal" if larger than the facial nerve, "hypoplastic" if equal or less [Heining et al., 2017] (Fig. 1); (2) the cochlear signal on precontrast T1-weighted fast spin echo (T1 FSE), 3D T2-weighted FFSP and 3D FLAIR; precontrast T1 FSE and 3D FLAIR sequences were performed to evaluate the eventual presence of blood product and/or proteinaceous content in the cochlea, respectively ( Fig. 2a, b) ; the enhancement on the 4-h delayed postcontrast 3D FLAIR sequence was measured as the ratio between the mean value of a polygonal region of interest (ROI) drawn on the middle turn of the cochlea (ROI area ≅ 6 mm 2 ) and the mean value of a circular ROI drawn on the cerebrospinal fluid at the level of the cerebellarpontine angle (online suppl. materials Fig. 1 ); these ratios were assessed for normal distribution with the Shapiro-Wilk test and further compared with the distribution of the corresponding ratios calculated in the 24 healthy ears. Values were defined as not normal if felt outside ±2 standard deviations from the mean; (3) the presence of vestibular (vEH) or cochlear endolymphatic hydrops (cEH) defined using Nakashima's quantitative method on 4-h delayed postcontrast 3D FLAIR sequence [Nakashima et al., 2009] (Fig. 3) .
Results
Four DFNA9-affected patients were enrolled (male = 2, female = 2; median age: 65.6 years) with a total of 8 diseased ears analyzed. Three patients were relatives; the fourth was unrelated and had no relatives to be tested. The control SSHL group counted 24 patients (males = 13, females = 11; median age: 53 years) with a total of 24 healthy ears analyzed. All selected DFNA9 patients were white Caucasians, and for all of them, next-generation sequencing revealed a pathogenic heterozygous mutation in the Limulus factor C, Coch-5b2 and Lgl1 domain of cochlin. The genetic profile of DFNA9 patients is reported in online supplementary materials Table 2 ; the missense heterozygous mutation in the COCH gene (NM_004086.2) was G88A in the three relatives and W117R in the other patient. The results of the audiological assessment are summarized in Table 1 . All the DFNA9 subjects suffered from bilateral progressive sensorineural hearing loss, more severely at the high frequencies, tinnitus and bilateral symmetrical labyrinthine hyporeflexia, embodying the typical clinical pattern of bilateral chronic degenerative cochleovestibular deficit. All patients complained of aural fullness from the onset of the disease, but none of them reported fluctuating hearing loss. The degree of hearing loss was moderately severe in 2 (one of them reported environmental exposure to acoustic trauma) and severe in 2 others. Transiently evoked otoacoustic emissions were not detectable in all cases. Vestibular dysfunction was observed in all DFNA9 patients: it was characterized by weakened bilateral semicircular canal function (areflexia in 1 out of 4 patients) by both vestibulo-ocular reflex, video head impulse test and caloric testing. Despite the poor or very poor bilateral response at caloric testing, the two males (patients No. 2 and 4) did not complain of vertigo spells and showed stat- No. 4 showed hypoplasia of the left cochlear nerve but no other signal abnormalities on precontrast imaging (Fig. 1) . As in the control group, none of the DFNA9 patients showed a significant vEH and cEH. Conversely, all DFNA9 ears showed a high bilateral contrast enhancement on 4-h delayed postcontrast 3D FLAIR sequence ( Fig. 2a ).
Discussion
Our study showed that the common imaging finding in DFNA9 ears is the higher enhancement of the perilymph, in both cochlear and vestibular spaces, on 4-h delayed postcontrast 3D FLAIR sequence. In addition, an increased signal on precontrast 3D FLAIR was also observed in our patients No. 1 and 3; patient No. 1 also showed an increased signal on precontrast T1-weighted The increased enhancement of the perilymph on 4-h delayed postcontrast 3D FLAIR sequence suggests the breakdown of the blood-labyrinthine barrier (BLB). The BLB is crucial for the maintenance of inner ear fluid ionic homeostasis, preventing the entry of toxic substances Fig. 3 . MR evaluation of cEH and vEH in patient No. 2 according to Nakashima criteria using 4-h delayed postcontrast FLAIR sequence. a On the axial plane parallel to the cochlear axis, cEH was "absent," in fact the cochlear duct is almost not detectable. b On the axial plane parallel to the lateral semicircular canal, the vestibular endolabyrinth (arrow) did not exceed the 33% of the entire area of the vestibule, which corresponded to "absent" vEH. into the inner ear [Ishiyama et al., 2018] . It has been demonstrated that the BLB is highly selective and that the composition of the inner ear fluids is regulated and markedly different from that of blood or of other fluids such as cerebrospinal fluid [Juhn et al., 2001; Ishiyama et al., 2017] . The contrast agent starts physiologically to accumulate in the perilymph after its intravenous administration, but not in the endolymph, crossing the BLB and reaching the maximum concentration at about 4.5 h from the administration [Naganawa et al., 2012] . As a consequence, postcontrast MRI acquired at about 4-5 h can distinguish the membranous labyrinth (hypointense) from the surrounding perilymph (hyperintense). In normal conditions the progressive enhancement of the perilymph should be symmetric, while an asymmetric enhancement at early and/or delayed postcontrast sequences indicates the BLB breakdown on the affected side [Berrettini et al., 2013 Conte et al., 2017 , 2018a . In the three ears in which the enhancement is more evident (Table 2) , the association of spontaneously increased signal on precontrast FLAIR suggests that the BLB breakdown caused the accumulation of proteinaceous material in the perilymph, among which possibly also cochlin. Cochlin, expressed in the osseous spiral lamina, spiral ligament, limbus and stroma of the maculae and cristae [Robertson et al., 1998; Li et al., 2005; Robertson et al., 2006] , is a secreted protein with three functional domains (Limulus factor C, Coch-5b2 and Lgl1 domain, vWFA1, vWFA2) likely to be involved in antibody-independent host defense mechanisms [Bhattacharya, 2006; Py et al., 2013; Bae et al., 2014] and to be associated with extracellular matrix proteins, typically fibrillar collagens [Khetarpal, 2000; Nagy et al., 2008] . Histopathological studies revealed that in DFNA9 patients cochlin protein aggregates in the extracellular matrix, altering protein-to-protein interactions [Robertson et al., 1998; Merchant et al., 2000; Khetarpal, 2000; Street et al., 2005; Bhattacharya, 2006; Robertson et al., 2006; Bae et al., 2014] , and possibly interfering with ionic homeostasis; it also accumulates in the spiral ligament, in the distal osseous spiral lamina, at the base of the spiral limbus and in mesenchymal tissue at the base of the vestibular neuroepithelium [Burgess et al., 2016 ]. An electron microscopic study by Khetarpal [2000] demonstrated that mutated cochlin can alter the normal interaction between fibrillar collagen type II and extracellular matrix in the spiral ligament, promoting collagen degradation. A direct toxic effect of the deposited material may cause severe degeneration of multiple cytological elements [Merchant et al., 2000; Robertson et al., 2006; Burgess et al., 2016] . Moreover, the cochlin von Willebrand domains have been suggested to play a key role in increasing shearinduced platelet aggregation [Bhattacharya, 2006] , possibly resulting in vascular disease with subsequent tissue degeneration. The direct toxic effect of protein aggregates and the induced vascular degeneration may play a causative role in the BLB breakdown. Interestingly, EH was not a prominent feature in DFNA9-affected patients, despite vestibular symptoms (patient No. 1 and 2) , bilateral hyporeflexia (patient No. 1, 3 and 4) or areflexia (patient No. 2) and abnormal vestibular reflexes. This finding seems to suggest that the pathogenesis and the progression of otovestibular symptoms in DFNA9 are not determined by vestibular EH. DFNA9 has often been confused with Ménière's disease, due to the similar clinical presentation especially in early stages [De Kok et al., 1999; Lemaire et al., 2003; Hildebrand et al., 2009] . In contrast, DFNA9 does not show signs of EH, which is instead a prominent pathophysiological feature of Ménière's disease [Nakashima et al., 2009] . As far as we know, this is the first study providing imaging evidence of absence of cEH and vEH, in agreement with and support to a previous report by Usami et al. [2003] who underlined the discrepancies between DFNA9 and Ménière's disease. Our patients No. 3 and 4 showed unilateral hypoplasia of the cochlear nerve, a finding which was not mentioned in previous DFNA9 studies. Hypoplasia of the cochlear nerve has been linked to profound deafness and reduced spiral ganglion cell count [Nadol and Xu, 1992; Kujawa and Liberman, 2009] . Interestingly, the reduced cochlear nerve diameter did not correlate with worse clinical performance (patients No. 3 and 4) . It should be kept in mind that the variability of diameters of cochlear nerves is wide in both hearing and deaf subjects [Nadol and Xu, 1992] . Nevertheless, our patients achieved a significant benefit from hearing aid amplification and cochlear implantation. Some limitations of our study should be acknowledged. The number of identified and enrolled DFNA9 cases is small, reflecting the low incidence of this pathology in the general population [Fransen and Van Camp, 1999; Usami et al., 2003; Chen et al., 2013] ; nonetheless 3 out of 4 enrolled DFNA9 patients belonged to the same family, and all the patients had long-standing disease with moderate-severe sensorineural hearing loss with vestibular hyporeflexia. Thus, our study could not rule out the possibility that clinical and MRI features of EH are present exclusively at the onset and in milder phenotypes. We could not provide histological data that would have better explained our MR findings, which is another limitation that has to be cited. DOI: 10.1159/000501292
Conclusion
Increased perilymph enhancement on 4-h delayed postcontrast 3D FLAIR sequence is the common imaging feature of DFNA9 ears, suggesting that BLB breakdown may play the main role in the pathophysiology of this disease. Although MRI did not detect significant hydrops in our DFNA9 cohort, prospective longitudinal studies should confirm our results as well as evaluate whether different DFNA9 mutations show similar MRI findings. This study suggests that advanced MRI might be clinically useful in differentiating DFNA9 disease mimicking Ménière's disease.
